Validation of New Symptom-Based Fibromyalgia Criteria for Irritable Bowel Syndrome Co-morbidity Studies by Sperber, Ami D et al.
JNM Journal of Neurogastroenterology and Motility 
Original Article
       
67
J Neurogastroenterol Motil,  Vol. 17  No. 1 January,  2011 
DOI: 10.5056/jnm.2011.17.1.67
ⓒ 2011 The Korean Society of Neurogastroenterology and Motility
J Neurogastroenterol Motil,  Vol. 17  No. 1 January,  2011
www.jnmjournal.org
Validation of New Symptom-Based Fibromyalgia 
Criteria for Irritable Bowel Syndrome Co-morbidity 
Studies
Ami D Sperber,
1,3,4,5* Smadar Akiva,
3 Moshe Leshno,
6 Zamir Halpern
5,7 and Dan Buskila
2,3
1Department of Gastroenterology and 
2Department of Medicine H, Soroka Medical Center, Beer-Sheva, Israel,  
3Faculty of Health Sciences and  
4Sial Research Center for Family Medicine and Primary Care, Ben-Gurion University of the Negev, Beer-Sheva, Israel, 
5Department of 
Gastroenterology and Liver Diseases, Tel-Aviv Medical Center, Tel-Aviv, Israel,  
6Faculty of Management and 
7Sackler Faculty of Medicine, 
Tel-Aviv University, Tel-Aviv, Israel
ㅋ
Background/Aims
There is significant co-morbidity between irritable bowel syndrome (IBS) and fibromyalgia syndrome (FMS). However, FMS is 
diagnosed by physical examination, which limits the conduct of co-morbidity studies in a large population-based study. The 
purpose of this study was to determine the diagnostic validity of a new symptom-based criteria in patients with FMS and/or 
IBS using the American College of Rheumatology (ACR) criteria as a gold standard.
Methods
The study participants consisted of women with FMS (n = 30), IBS (n = 27) and controls (n = 28). A new symptom-based di-
agnostic criteria for FMS comprised a regional pain scale and a visual analogue scale for fatigue. All subjects underwent a 
physical examination for FMS (ACR criteria) and structured questionnaires of regional pain scale and visual analogue scale for 
fatigue. A fibromyalgia intensity score was calculated and thresholds of tenderness were determined by a dolorimeter. 
Results
The number of participants diagnosed with FMS in the entire study population (n = 85) was 31 by the new criteria. Compared 
to the ACR, the sensitivity of the new criteria was 82.9%, specificity 96.0%, positive predictive value 93.5% and negative pre-
dictive value 88.9%. In addition, new criteria were useful for the diagnosis of FMS among the subjects with IBS. A fibro-
myalgia intensity score was significantly correlated with the threshold of tenderness (r = -0.62, P < 0.001). 
Conclusions
The new symptom-based diagnostic criteria for the diagnosis of FMS can be used in large-scale clinical and epidemiological 
co-morbidity studies, in which physical examination is unfeasible. Gastroenterologists investigating the effects of co-morbid 
FMS in IBS patients can use these new ciriteria with confidence.
(J Neurogastroenterol Motil 2011;17:67-72)
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Introduction
Irritable bowel syndrome (IBS) and fibromyalgia syndrome 
(FMS) are common functional disorders that share many cha-
racteristics. The prevalence of FMS among IBS patients ranges 
from 30% to as high as 70% in published studies.
1-3 Our group 
reported that 32.4% of IBS patients met the American College of 
Rheumatology (ACR) diagnostic criteria for FMS and 32% of 
FMS patients met the Rome II diagnostic criteria for IBS.
3 We 
also found that patients with both disorders have more severe IBS 
symptoms, more psychopathology, lower health-related quality of 
life
4 and a lower score on the sense of coherence questionnaire 
for coping skills
5 than patients with only one of these disorders. 
FMS is a soft tissue disorder characterized by diffuse muscu-
loskeletal pain and specific tender points on physical examination. 
FMS is diagnosed in accordance with the ACR criteria of 1990,
6 
namely widespread pain in combination with tenderness of 11 or 
more of the 18 specific tender point sites on physical examination.
Since many IBS and FMS patients have concomitant func-
tional disorders in other body systems, eg, the chronic fatigue 
syndrome, the possibility of a common pathogenesis has been 
raised.
7-11 Large-scale clinical studies and epidemiological sur-
veys could advance our understanding of these associations in 
terms of pathogenesis, the impact on symptom severity, health- 
related quality of life and patient care.
The diagnosis of IBS is symptom-based
12 and is established 
mostly by the Rome criteria questionnaire.
13 In contrast, the diag-
nosis of FMS requires physical examination by a trained exami-
ner. This situation makes research into co-morbidity between 
FMS and other functional disorders, such as IBS, difficult, time 
consuming and inconvenient for the patient and the investigator. 
In effect, large-scale clinical or epidemiological studies of co- 
morbidity between FMS and IBS are not feasible due to this 
limitation. Wolfe and Michaud
14,15 developed and validated new 
criteria to diagnose FMS without requiring physical examina-
tion. The criteria are a composite score of their regional pain 
scale (RPS) and a visual analog scale (VAS) for chronic fatigue 
(for details see the Methods section below). In a validation study 
of 12,799 patients with rheumatic disease, Wolfe
14 found a con-
cordance rate of 73% between the ACR criteria and the new 
criteria. The authors concluded that the new criteria are useful for 
the diagnosis of FMS and have the advantage of not requiring 
physical examination.
The purpose of this study was to determine the test character-
istics of the new diagnostic criteria in a population of IBS and 
FMS patients, as well as healthy controls, using the ACR criteria 
as the gold standard. The expectation is that the new criteria 
could be used in the future to facilitate studies of co-morbidity 
between IBS, FMS and other functional disorders.
Materials and Methods
Study Groups
The study population was comprised of women with FMS, 
women with IBS and female controls. The IBS patients and the 
controls were matched by age to the FMS patients. The women 
were recruited from the FMS and Gastroenterology clinics in the 
Soroka Medical Center, Beer-Sheva, Israel between January 2007 
and March 2008. The FMS patients were recruited and tested 
first. IBS patients and controls were then matched by age (± 3 
years) to the FMS group. The study group was comprised of 
women because this is a female-predominant disorder and we 
wanted to avoid potential confounders in this initial applicability 
study. The study was approved by the Helsinki committee (In-
ternal Review Board) of the Soroka Medical Center. After re-
ceiving detailed information about the design of the study and its 
objectives and providing signed informed consent, each partic-
ipant completed the survey questionnaire and underwent a phys-
ical examination to diagnose FMS, including palpation of tender 
points and determination of tenderness thresholds.
Diagnostic Criteria
American College of Rheumatology criteria for fibromy-
algia syndrome (1990)
The ACR classification criteria of 1990 served as the gold 
standard. The ACR criteria are defined as: 
Widespread pain has been present for at least 3 months. Pain 
is considered widespread when it is: (1) in both sides of the body 
and (2) above and below the waist. In addition, axial skeletal pain 
(cervical spine, anterior chest, thoracic spine or low back pain) 
must be present. Low back pain is considered lower segment 
pain. Finally, pain on digital palpation must be present in at least 
11 of 18 defined tender point sites.
New composite score criteria for fibromyalgia syndrome
The diagnosis of FMS using the new criteria was based on a 
composite score of a survey questionnaire (RPS) and a VAS for 
fatigue, as follows: 
Regional pain scale. This questionnaire is comprised of a IBS Co-morbidity Research
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list over 19 body areas. For each area the respondent was re-
quested to grade the amount of pain or tenderness they felt in the 
specific area over the previous 7 days on a 4-item Likert scale of 
“none,” “mild,” “moderate” and “severe.” Any response other than 
“none” was considered a positive response. Thus, the range of 
possible positive responses was 0-19, as each of the 19 body areas 
could yield a positive or negative score. A total positive score for 8 
or more areas was required for the diagnosis of FMS (see diag-
nosis of FMS, below). The RPS was translated into Hebrew and 
the translation was validated using the method published by one 
of the authors.
16
Chronic fatigue visual analog scale. Participants were re-
quested to mark the degree of fatigue they felt over the previous 
week on a VAS scale from 0-10. A score of 6 or greater was re-
quired for the diagnosis of FMS.
Composite score for the new diagnosis of fibromyalgia 
syndrome
FMS was diagnosed if RPS ≥ 8 and VAS ≥ 6. 
Irritable bowel syndrome
The diagnosis of IBS was based on the Rome II criteria, 
which were the latest update of the Rome criteria at the time the 
study was conducted.
Study Protocol
Each participant in the 3 study groups visited once in the 
study and the following variables were determined at that time: 
(1) number of tender points (of 18), by physical examination; (2) 
threshold of tenderness at tender points, by dolorimeter; and (3) 
FMS by RPS and chronic fatigue VAS. 
The same investigator preformed all tender point and pres-
sure threshold tests, described below, in all the study participants 
after being trained in the implementation of the tests by an expert 
rheumatologist with extensive experience.
Tender Point Count
The count of the 18 tender points was performed by thumb 
palpation at 9 symmetrical point sites. At first, manual pressure 
was demonstrated at a control site. Patients were told to expect a 
sensation of pressure, and to indicate if and when it became 
painful. Definite tenderness at any site was considered present if 
some involuntary verbal or facial expression of pain occurred, or a 
wince or withdrawal was observed. The amount of manual pres-
sure over each tender point was about 4 kg/cm
2, as determined by 
a dolorimeter. 
Pressure Thresholds
Pressure thresholds were assessed by a Chatillon dolorimeter 
(Chatillon Instruments, New York, NY, USA), a small instru-
ment that has a maximum scale of 9 kg, with a neoprene stopper 
as footplate and a diameter of 1.4 cm,
17 at 13 sites (9 tender point 
sites and 4 control sites). The footplate was placed on a tender 
point and stabilized, if necessary, by the examiner’s non-domi-
nant hand to prevent (often painful) shifting of the footplate un-
der pressure, while taking care not to add or subtract from the 
force applied. The dolorimeter was held close to the vertical po-
sition. Pressure was increased at a rate of about 1 kg/sec. The 
subject was asked to say “yes” when the sensation was no longer 
pressure, but became definite pain. Preliminary measures of con-
trol sites were done to familiarize the subject with the process and 
to discourage anticipation and/or exaggerated responses.
The intensity of FMS (FI) was calculated by means of the 
formula developed and validated by Wolfe et al (personal com-
munication) as follows: 
FI = (VAS [fatigue] + [RPS/2])/2
Statistical Methods
Sample size calculations determined that the required num-
ber of participants in each study group was 25 with α=0 . 0 5  
and 1-β = 80%. The required sample size to characterize the 
sensitivity of new criteria was calculated as described by Li and 
Fine,
18 by testing H0: Se = Se0 versus H1: Se = Se1 ≠ Se0, 
where Se stands for sensitivity (Sp, for specificity, replaces Se in 
all calculations of specificity). By applying a standard normal ap-
proximation, we calculated the required number of patients with 
disease by using the following formula:
2
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where n1 is the number of patients needed with α as the sig-
nificance level, 1-β is the power of the test and Zα and Zβ are up-
perαand β quantiles of the standard normal distribution, respec-
tively. The total population is n1/p where p is the prevalence of the 
disease. In our case, assuming Se0 =0 . 7  a n d  S e 1 = 0.9, the re-
quired sample size was 25.
In addition to the cutoff points defined by Wolfe and Mi-
chaud
14,15 for the diagnosis of FMS with the new composite 
score, specificity and sensitivity rates were determined for a range Ami D Sperber, et al
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Table 1. Test Characteristics of Fibromyalgia Syndrome by Ori-
ginal Composite Score Compared to Gold Standard Test for Entire
Study Population (N = 85)
Test
Composite score
a
Total
+   −
ACR + 29   6 35
−   24 85 0
Total 31 54 85
aComposite score = RPS ≥ 8 and VAS ≥ 6.
ACR, American College of Rheumatology; RPS, regional pain scale; VAS, 
visual analog scale.
Sensitivity = 82.9%, specificity = 96.0%, positive predictive value = 93.5%, 
negative predictive value = 88.9%.
Table 2. Test Characteristics of Fibromyalgia Syndrome by Mo-
dified Composite Score Compared to Gold Standard Test for En-
tire Study Population (N = 85)
Test
Composite score
a
Total
+   −
ACR + 31   4 35
−   14 95 0
Total 32 53 85
aComposite score = RPS ≥ 11 and VAS ≥ 5.
Abbreviations as in Table 1.
Sensitivity = 88.6%, specificity = 98.0%, positive predictive value = 96.9%, 
negative predictive value = 92.5%.
Table 3. Test Characteristics of Fibromyalgia Syndrome by Ori-
ginal Composite Score Compared to Gold Standard Test for Pa-
tients With Irritable Bowel Syndrome (n = 27)
Test
Composite score
a
Total
+   −
ACR +  3   2   5
−  02 2 2 2
Total  3 24 27
aComposite score = RPS ≥ 8 and VAS ≥ 6.
Abbreviations as in Table 1.
Sensitivity = 60.0%, specificity = 100.0%, positive predictive value = 100.0%, 
negative predictive value = 91.7%.
Table 4. Test Characteristics of Fibromyalgia Syndrome by Mo-
dified Composite Score Compared to Gold Standard Test for Pa-
tients With Irritable Bowel Syndrome (n = 27)
Test
Composite score
a
Total
+   −
ACR +  3   2   5
−  12 1 2 2
Total  4 23 27
aComposite score = RPS ≥ 11 and VAS ≥ 5.
Abbreviations as in Table 1.
Sensitivity = 60.0%, specificity = 95.5%, positive predictive value = 75.0%, 
negative predictive value = 91.3%.
of other cutoff points to see if any other cutoff point would gen-
erate better sensitivity and specificity than the pre-determined 
ones.
The Pearson’s correlation coefficient was used to determine 
the correlation between the dolorimeter test of pain sensitivity 
(threshold) and the FI score from the survey questionnaire. Sta-
tistical significance was set at P ≤ 0.05.
Results
The final study population was comprised of 30 FMS pa-
tients, 27 IBS patients and 28 controls. The mean age (± SD) 
was 51.7 ± 12.9, 53.1 ± 12.4 and 48.8 ± 12.1, respectively (P
= 0.41). Thirty-seven women in the 3 groups were diagnosed 
with FMS, 35 by the ACR criteria and 31 by RPS. Twenty-nine 
of these were diagnosed by both tests.
Test Characteristics (Sensitivity, Specificity and 
Positive and Negative Predictive Values)
The sensitivity and specificity of the new composite diag-
nostic score for FMS were determined using the ACR criteria as 
the gold standard. These test characteristics were determined for 
the 85 women in the study population using the original cutoff 
points (composite score = RPS ≥ 8 and VAS ≥ 6) (Table 1). 
The sensitivity and specificity were 82.9% and 96.0%, respec-
tively and the positive and negative predictive values were 93.5% 
and 88.9%, respectively. 
Several other cutoff points were also analyzed. The best test 
characteristics were found when the composite score for FMS 
was defined as RPS ≥ 11 and VAS ≥ 5 (Table 2). The sensi-
tivity and specificity were 88.6% and 98.0%, respectively, for the 
entire study population. The positive and negative predictive val-
ues were 96.9% and 92.5%, respectively. 
We did separate analyses in the subgroup of patients with 
IBS group (n = 27). The positive predictive value of the new IBS Co-morbidity Research
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composite score for FMS in IBS group was 100.0%, negative 
predictive factor 91.7% with relatively low sensitivity (Tables 3 
and 4).
Association Between Pain Thresholds by Dolo-
rimeter and the Fibromyalgia Intensity Score
The dolorimeter determination of sensitivity threshold in the 
physical examination and the FI calculated on the basis of the 
RPS reflect a similar dimension. The mean FI was 8.4 for the 
FMS group and 3.8 for the IBS group. The Pearson’s correla-
tion coefficient between threshold of tenderness by dolorimeter 
and the FI was -0.62 (P < 0.001). Thus, greater symptom in-
tensity was inversely correlated with the threshold for pain and 
the correlation was statistically significant.
Discussion
The high rate of co-morbidity between functional disorders 
such as IBS and FMS and their shared characteristics have led 
some experts to propose that they share a common pathogenesis 
or even represent a single entity that has been split into separate 
diagnoses because of the hyper-specialization of the medical 
profession.
19 Studies of the prevalence of co-morbidity between 
these 2 disorders and other functional disorders have the potential 
of increasing our understanding of each disorder and the links 
among them as well as contributing to the improvement of patient 
care.
However, co-morbidity studies that involve FMS are se-
verely limited in scope by the need to perform a physical examina-
tion to determine the diagnosis on the basis of the ACR criteria of 
1990.
6 The conduct of large-scale clinical as well as epidemio-
logical studies is unfeasible because of this limitation. In recog-
nition of this problem, Wolfe
14 developed the RPS as an alter-
native method to diagnose FMS in the research setting. Before 
using new study instruments (such as the RPS) and new diag-
nostic criteria (such as the composite score to diagnose FMS) in 
epidemiological and clinical studies, they must be validated by as-
sessment of the test characteristics, in particular sensitivity, spe-
cificity and positive and negative predictive values, respectively.
The results of the present study, taken together with the vali-
dation studies published by Wolfe and Michaud,
14,15 demonstrate 
that the RPS can be used as a valid substitute for the ACR criteria 
when large study groups make the physical examination unprac-
tical or for epidemiological surveys that are conducted in large 
populations by mail, telephone or other indirect means. 
Both the sensitivity and specificity calculated in this study 
(82.9% and 96.0%, respectively) are acceptable. The higher spe-
cificity rate means that there are few false positives, while the 
somewhat lower sensitivity rates means that there could be some 
false negatives. Thus, studies of co-morbidity using these criteria 
could present a slight underestimate of the actual co-morbidity 
rates, which we believe is more acceptable than an overestimate. 
When analyzing other potential cutoff points, we calculated a sen-
sitivity of 88.6% with a specificity of 98.0% using RPS ≥ 11 and 
VAS ≥ 5. This finding is of particular interest in that the num-
ber of painful regions by RPS (≥ 11) corresponds with the mini-
mum number of tender points required by the ACR at physical 
examination (≥ 11). While we cannot recommend to use this 
cutoff point based solely on this finding, we do recommend the 
conduct of further validation studies that may show it to be a 
more useful cutoff for studies of co-morbidity between IBS and 
FMS in that it can provide us with a more accurate estimate of 
co-morbidity rates. 
A limitation of this study is the restriction to female patients. 
This was done because IBS is a female-predominant disorder, as 
is fibromyalgia, and we wanted to have a homogeneous popula-
tion to avoid potential confounders. This decision limits the gen-
eralizability of the results somewhat. Two other potential limi-
tations of this study are that we did not ascertain the prevalence of 
IBS among FMS patients and that the propensity for reporting 
pain in IBS patients could lead to biased results.
In conclusion, gastroenterologists and other investigators in-
terested in co-morbidity between IBS and FMS, as well as addi-
tional functional disorders and unexplained symptoms, can use 
the survey questionnaire (RPS). The new criteria can be used in 
large-scale general population-based studies and not only on stu-
dies of patient populations with IBS and other functional disor-
ders. This is of interest because in each disorder there are many 
“non-patients” who are only identified through population-based 
surveys. For example, it might be used in a population survey 
looking into prevalence rates for different functional disorders 
from which we could learn about consultation behavior and dif-
ferences between “consulters” and “non-consulters.” The latter 
could not be done with the ACR criteria because of the need for 
physical examination. By enabling the conduct of large-scale clin-
ical and epidemiological studies, our understanding would be 
broadened on the pathogenesis of co-morbid conditions and the 
implications for patients in terms of impact on symptom severity 
and health-related quality of life as well as potentially leading to 
improved patient care.Ami D Sperber, et al
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